SG11202104276YA - Peptide fragments for treatment of diabetes - Google Patents

Peptide fragments for treatment of diabetes

Info

Publication number
SG11202104276YA
SG11202104276YA SG11202104276YA SG11202104276YA SG11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA
Authority
SG
Singapore
Prior art keywords
diabetes
treatment
peptide fragments
fragments
peptide
Prior art date
Application number
SG11202104276YA
Other languages
English (en)
Inventor
Jan Alenfall
Maria Ekblad
Pontus Dunér
Original Assignee
Follicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follicum Ab filed Critical Follicum Ab
Publication of SG11202104276YA publication Critical patent/SG11202104276YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202104276YA 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes SG11202104276YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18204862 2018-11-07
PCT/EP2019/080563 WO2020094797A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Publications (1)

Publication Number Publication Date
SG11202104276YA true SG11202104276YA (en) 2021-05-28

Family

ID=64183928

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104276YA SG11202104276YA (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Country Status (13)

Country Link
US (2) US20220002343A1 (https=)
EP (1) EP3876970A1 (https=)
JP (1) JP7553115B2 (https=)
KR (1) KR20210088583A (https=)
CN (1) CN113164548A (https=)
AU (1) AU2019374981A1 (https=)
BR (1) BR112021008888A2 (https=)
CA (1) CA3116612A1 (https=)
IL (1) IL282519A (https=)
MX (1) MX2021005386A (https=)
SG (1) SG11202104276YA (https=)
WO (1) WO2020094797A1 (https=)
ZA (1) ZA202102572B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
JP2025516717A (ja) * 2022-05-13 2025-05-30 コーギン ファーマ エービー 血管新生を誘発する薬剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505750A (ja) * 1994-09-16 1998-06-09 ザ スクリップス リサーチ インスティテュート 粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
WO2004015390A2 (en) 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN100503637C (zh) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
US9044438B2 (en) * 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2114422A1 (en) * 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201406989D0 (en) * 2014-04-17 2014-06-04 Follicum Ab Novel treatments
CA3061935A1 (en) * 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes

Also Published As

Publication number Publication date
AU2019374981A1 (en) 2021-05-27
BR112021008888A2 (pt) 2021-08-17
KR20210088583A (ko) 2021-07-14
ZA202102572B (en) 2022-10-26
US20240327459A1 (en) 2024-10-03
CA3116612A1 (en) 2020-05-14
IL282519A (en) 2021-06-30
US20220002343A1 (en) 2022-01-06
WO2020094797A1 (en) 2020-05-14
JP2022516400A (ja) 2022-02-28
EP3876970A1 (en) 2021-09-15
MX2021005386A (es) 2021-07-06
JP7553115B2 (ja) 2024-09-18
CN113164548A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
GB201804514D0 (en) Treatment of pyroptosis
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL270199A (en) Peptides for the treatment of diabetes
EP3256158A4 (en) Tolerance therapeutic for treating polypeptide induced allergy
GB201805100D0 (en) Treatment of sarcopenic diseases
GB201707207D0 (en) Treatment of type 1 diabetes
GB201804515D0 (en) Treatment of necroptosis
IL282519A (en) Peptide fragments for the treatment of diabetes
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
PT3833378T (pt) Tratamento de verrugas
IL284029A (en) Peptides for the treatment and prevention of diabetes and related disorders
IL263564B (en) Peptides for the treatment of osteoarthritis
EP3628048A4 (en) PEPTIDES FOR CANCER TREATMENT
IL250666A0 (en) A peptide for the treatment of diabetes mellitus type 2 and its complications
HK40058402A (en) Peptide fragments for treatment of diabetes
IL282952A (en) A method for improving peptide kinetics in them
SG11202102683XA (en) Treatment for obesity
GB201915003D0 (en) Treatment of hepatotoxicity
HK40068631A (en) Treatment of diabetes
GB201700849D0 (en) Citrullinated peptides for diagnosis or treatment of diabetes
GB201805099D0 (en) Treatment of osteoporotic diseases
HK40018947A (en) Peptides and methods for the treatment of diabetes
GB201904282D0 (en) Treatment of osteoporotic diseases
GB201907839D0 (en) Treatment of hepatotoxicity